Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. More: Novo to knock down Ozempic, Wegovy list prices
read more
Erythromelalgia treatment gains regulatory support following EMA decision More: ACD440 granted orphan drug status in the EU Source: News
read more
PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens More: ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato Source: News
read moreAstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal. More: AstraZeneca CEO pay hits .9M amid ‘significant geopolitical uncertainty’ in
read moreJust three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market. More: BioMarin pulls hemophilia gene therapy Roctavian, taking 0M hit
read moreLooking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with the potential for a weight
read more© 1994 - 2026 B.M. Pharmaceuticals